Fundraising Fox

Atea Pharmaceuticals

NASDAQ: AVIR

Boston, US · Founded 2012 · Massachusetts corporation · 2 known investors

ateapharma.com

Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV). Its work spans antiviral drug discovery, medicinal chemistry, biology, and virology.

BiotechHealthtech

Founders & leadership

Atea Pharmaceuticals was founded in 2012 by Jean-Pierre Sommadossi, Ph.D..

JS
Jean-Pierre Sommadossi, Ph.D.Founder

Board

BL
Bruno LucidiBoard director
EZ
Evgeny ZatsevBoard director
FY
Frank YuBoard director
GC
Gerald ChanBoard director
BP
Bruce PolskyBoard director

Investors · 2

Reported raises · per SEC filings

Form D private placements

$175.9M disclosed across 4 rounds · 2013–2020

$107.5MraisedMay 2020 · 37 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jean-Pierre Sommadossi, Ph.D.Executive Officer, Director
  • Andrew Hack, M.D., Ph.D.Director
  • Bruno LucidiDirector
  • Bruce PolskyDirector
  • Andrea CorcoranExecutive Officer
  • Bihua ChenDirector
  • Franklin BergerDirector
  • Grigory BorisenkoDirector
  • Isaac Cheng, M.D.Director
Offering amount
$215M
Amount sold
$107.5M
Sales commissions
$500K
Placement agents
William Blair
First sale
May 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$27.6MraisedJul 2018 · 38 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gerald ChanDirector
  • Evgeny ZatsevDirector
  • Jean-Pierre SommadossiExecutive Officer, Director
  • Bruce PolskyDirector
  • Fan YuDirector
  • Andrea CorcoranExecutive Officer
  • Bihua ChenDirector
  • Bruno LucidiDirector
Offering amount
$27.6M
Amount sold
$27.6M
Sales commissions
$119.5K
Placement agents
CIM Securities, LLC
First sale
Jun 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$20.8MraisedSep 2016 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruno LucidiDirector
  • Jean-Pierre Sommadossi, Ph.D.Executive Officer, Director
  • Evgeny ZatsevDirector
  • Frank YuDirector
  • Gerald ChanDirector
  • Bruce PolskyDirector
Offering amount
$20.8M
Amount sold
$20.8M
Sales commissions
$167K
Placement agents
CIM Securities
First sale
Aug 2016
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$20MraisedSep 2014 · 59 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Jean-Pierre Sommadossi, Ph.D.Executive Officer, Director
Offering amount
$20M
Amount sold
$20M
Minimum investment
$25K
Sales commissions
$811.1K
Placement agents
Brookline Group, LLC
First sale
Dec 2013
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Companies competing with Atea Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Atea Pharmaceuticals do?
Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV). Its work spans antiviral drug discovery, medicinal chemistry, biology, and virology.
Who founded Atea Pharmaceuticals?
Atea Pharmaceuticals was founded by Jean-Pierre Sommadossi, Ph.D. in 2012.
Who are Atea Pharmaceuticals's investors?
Atea Pharmaceuticals's investors include Bain Capital Life Sciences, RA Capital.
How much funding has Atea Pharmaceuticals raised?
Atea Pharmaceuticals has disclosed $175.9M raised across 4 rounds.
Where is Atea Pharmaceuticals headquartered?
Atea Pharmaceuticals is headquartered in Boston, US.